Liposomal doxorubicin

Journal of Drug Targeting
P G TardiP R Cullis

Abstract

Doxorubicin is a potent antineoplastic agent with activity against numerous human cancers. Encapsulation of doxorubicin inside a liposome alters bioavailability, biodistribution and thus its biological activity significantly. The physical properties of the liposome (size, lipid components and lipid dose) play a major role in determining drug retention and pharmacokinetics. The therapeutic benefits of liposomal doxorubicin will therefore depend on these physical characteristics. Here we review the toxicity and efficacy of liposomal doxorubicin determined for various liposome compositions (size, lipid composition and drug-to-lipid ratio). These physical properties can be independently varied using the transmembrane pH gradient-dependent drug encapsulation procedure. The results show that the toxicity of the formulation is related to drug retention in the circulation. The antitumor activity is more sensitive to the size of the liposomes. By optimizing these parameters, liposomal doxorubicin formulations can be optimized for improved therapeutic activity.

References

Dec 28, 1979·Biochemical and Biophysical Research Communications·E A Forssen, Z A Tökes
Aug 1, 1991·Trends in Biotechnology·P R CullisM J Hope
Nov 1, 1992·Biophysical Journal·P R HarriganP R Cullis
Apr 1, 1992·Biopharmaceutics & Drug Disposition·H HarashimaH Kiwada
Dec 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·D PapahadjopoulosC Redemann
Mar 1, 1990·Chemistry and Physics of Lipids·T D MaddenP R Cullis
Nov 2, 1990·Biochimica Et Biophysica Acta·G Blume, G Cevc
Nov 7, 1990·Journal of the National Cancer Institute·J TreatA Rahman
Jan 1, 1990·Cancer Chemotherapy and Pharmacology·M B BallyL D Mayer
Mar 30, 1990·Biochimica Et Biophysica Acta·M B BallyL D Mayer
Jun 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A RahmanP V Woolley
Sep 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·A Gabizon, D Papahadjopoulos
May 9, 1986·Biochimica Et Biophysica Acta·L D MayerP R Cullis
Jul 11, 1985·Biochimica Et Biophysica Acta·L D MayerA S Janoff
Dec 23, 1981·Biochimica Et Biophysica Acta·R M Abra, C A Hunt
Feb 1, 1982·European Journal of Cancer & Clinical Oncology·F OlsonF Szoka
Jan 1, 1993·Cancer Chemotherapy and Pharmacology·B A ConleyD A Van Echo

❮ Previous
Next ❯

Citations

Dec 8, 2005·Cancer Chemotherapy and Pharmacology·Jubo LiuChristine Allen
Aug 1, 1998·Journal of Controlled Release : Official Journal of the Controlled Release Society·L ClaryP Vierling
Oct 31, 1998·Journal of Controlled Release : Official Journal of the Controlled Release Society·M YokoyamaK Kataoka
Feb 1, 2003·Vaccine·Gretchen L OshopRobert A Heckert
Oct 27, 1998·AIDS Research and Human Retroviruses·C SmithG D Miralles
Sep 9, 2010·Biological & Pharmaceutical Bulletin·Atsuko HiokiYoshie Maitani
Jul 27, 2000·Photochemistry and Photobiology·R H BisbyC G Morgan
Aug 25, 2007·Nanomedicine·Dawn N Waterhouse, Marcel B Bally
Aug 9, 2012·Future Cardiology·Danielle HarakeSteven E Lipshultz
Sep 4, 2014·Chemical Communications : Chem Comm·Shoji TachikawaHiroyuki Nakamura
May 20, 2008·Pediatric Hematology and Oncology·A RuggieroR Riccardi
Jul 9, 2008·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Qing ChenFan Yuan
Dec 17, 2014·International Journal of Molecular Sciences·Jaromir GumulecMichal Masarik
Mar 2, 2006·Expert Opinion on Drug Delivery·Vijay I KulkarniRayasa R Murthy
Nov 28, 2009·Expert Opinion on Drug Delivery·Yi ShiLuk Chiu Li
Dec 11, 2002·Expert Opinion on Pharmacotherapy·Gerald BatistLauri Welles
Nov 22, 2005·Expert Opinion on Drug Delivery·Sérgio SimõesMaria Pedroso de Lima
Feb 19, 2000·Journal of Drug Targeting·M YokoyamaK Kataoka
Nov 28, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Claudia LangebrakeJörg Ritter
Jun 26, 2007·Journal of Pharmaceutical Sciences·Xiaobin B ZhaoRobert J Lee
Dec 15, 2012·Journal of Colloid and Interface Science·Xavier MuletCalum J Drummond
Oct 23, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Morten B HansenDennis W P M Löwik
Feb 7, 2012·Nanomedicine : Nanotechnology, Biology, and Medicine·Wenbing DaiQiang Zhang
Sep 22, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ashay JainGovind P Agrawal
Jul 25, 2009·Journal of Pharmaceutical and Biomedical Analysis·Hee Seung Kim, Irving W Wainer
Dec 15, 2005·British Journal of Haematology·Karlijn A WoutersSteven E Lipshultz
Feb 2, 2006·NMR in Biomedicine·Willem J M MulderKlaas Nicolay
Jan 29, 2013·Journal of Peptide Science : an Official Publication of the European Peptide Society·Antonella AccardoDiego Tesauro
Nov 30, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·Maria Laura ImmordinoLuigi Cattel
Aug 22, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·Masamichi NakayamaMasayuki Yokoyama
Feb 19, 2005·Seminars in Oncology·Michael S EwerAlberto A Gabizon
Oct 6, 2000·Biochimica Et Biophysica Acta·A L Bailey, S M Sullivan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.